Tampa, Florida 33612

  • Lung Cancer, Protection Against


The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.


Inclusion Criteria: - Male or female, 55 years of age or older - Former smokers and current enrolled in LDCT lung cancer screening or those who are detected using a regular CT, and have Lung-RADS 3 category lesion(s), that would get a 6 month f/u LDCT or regular CT based on Lung-RADS recommendations or former and current smokers enrolled in LDCT lung cancer screening, or regular CT and have Lung-RADS 2 category lesions with persistent or slowly increasing part-solid or non-solid lung nodule >4mm mean diameter detected by two serial yearly screening low dose CT or regular CT scans. - History of cigarette smoking with ≥ 20 pack years - All current smokers should accept to receive smoking cessation - Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1 - Able to swallow study pills - Able to undergo CT - Not allergic to components of study agents - Willing to discontinue current vitamin/mineral supplement use containing components of study agents. A standard multivitamin supplement provided for the study - Willing to comply with proposed visit and treatment schedule - Able to understand and willing to sign a written informed consent document - Participants must have normal organ and marrow function - Willing to use contraception during the intervention period of 6 months (males and females) - Not pregnant or lactating nor planning to become pregnant or lactate during the 6 month study intervention period.. Exclusion Criteria: - Invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell carcinoma) diagnosed within the last 2 years - Inability to undergo CT - Newly diagnosed nodule meeting Lung-RADS 4 criteria - Have taken doxycycline or tetracycline less than or equal to 2 weeks - Females- pregnant or lactating (throughout the duration of intervention of 6 months) - Unwilling to use effective form of birth control (Males and females) (throughout the duration of intervention of 6 months).



Primary Contact:

Principal Investigator
Nagi Kumar, Ph.D
H. Lee Moffitt Cancer Center and Research Institute

Backup Contact:


Location Contact:

Tampa, Florida 33612
United States

Kayoko Kennedy
Phone: 813-745-1947
Email: kayoko.kennedy@moffitt.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 21, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.